In the open-label PAPE study in 61 acromegaly patients, which showed that switching from first-generation somatostatin analogues to pasireotide monotherapy or a pasireotide and pegvisomant combination could control IGF1 levels in most patients, improvements in quality of life in a subset of patients on pasireotide were driven by improvements in fatigue and headache (18, 19). The gene discussed is IGF1; the disease is acromegaly.